Drug Profile
Buspirone/Zolmitriptan - Contera Pharma
Alternative Names: AV-2860; JM-010Latest Information Update: 19 Jan 2024
Price :
$50
*
At a glance
- Originator Contera Pharma
- Developer Bukwang Pharmaceutical; Contera Pharma
- Class Antidepressants; Antimigraines; Antiparkinsonians; Anxiolytics; Oxazolidinones; Pyrimidines; Small molecules; Spiro compounds; Tryptamines
- Mechanism of Action 5-HT1A serotonin receptor agonists; Dopamine modulators; Neurotransmitter agents; Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Drug-induced dyskinesia
Most Recent Events
- 17 Jan 2024 Phase-II clinical trials in Drug-induced dyskinesia in Slovakia, South Korea (PO)
- 17 Jan 2024 Safety and pharmacodynamics data from a preclinical studies in drug induced dyskinesia released by Contera pharma
- 30 Nov 2022 Korean Ministry of Food and Drug safety approves IND application for JM 010 in dyskinesia